Yergey JA - Search Results

1

In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.

Chauret N, Li C, Ducharme Y, Trimble LA, Yergey JA, Ramachandran C, Nicoll-Griffith DA. Chauret N, et al. Among authors: yergey ja. Drug Metab Dispos. 1995 Jan;23(1):65-71. Drug Metab Dispos. 1995. PMID: 7720527

2

Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).

Nicoll-Griffith DA, Chauret N, Yergey JA, Trimble LA, Favreau L, Zamboni R, Grossman SJ, Drey J, Herold E. Nicoll-Griffith DA, et al. Among authors: yergey ja. Drug Metab Dispos. 1993 Sep-Oct;21(5):861-7. Drug Metab Dispos. 1993. PMID: 7902249

3

CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humans.

Grossman SJ, Herold EG, Drey JM, Alberts DW, Umbenhauer DR, Patrick DH, Nicoll-Griffith D, Chauret N, Yergey JA. Grossman SJ, et al. Among authors: yergey ja. Drug Metab Dispos. 1993 Nov-Dec;21(6):1029-36. Drug Metab Dispos. 1993. PMID: 7905381

4

Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.

Nicoll-Griffith DA, Gupta N, Twa SP, Williams H, Trimble LA, Yergey JA. Nicoll-Griffith DA, et al. Among authors: yergey ja. Drug Metab Dispos. 1995 Oct;23(10):1085-93. Drug Metab Dispos. 1995. PMID: 8654196

5

Integrated application of capillary HPLC/continuous-flow liquid secondary ion mass spectrometry to discovery stage metabolism studies.

Li C, Chauret N, Ducharme Y, Trimble LA, Nicoll-Griffith DA, Yergey JA. Li C, et al. Among authors: yergey ja. Anal Chem. 1995 Sep 1;67(17):2931-6. doi: 10.1021/ac00113a030. Anal Chem. 1995. PMID: 8779418

6

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

Delorme D, Ducharme Y, Brideau C, Chan CC, Chauret N, Desmarais S, Dubé D, Falgueyret JP, Fortin R, Guay J, Hamel P, Jones TR, Lépine C, Li C, McAuliffe M, McFarlane CS, Nicoll-Griffith DA, Riendeau D, Yergey JA, Girard Y. Delorme D, et al. Among authors: yergey ja. J Med Chem. 1996 Sep 27;39(20):3951-70. doi: 10.1021/jm960301c. J Med Chem. 1996. PMID: 8831761

7

Refinement of an in vitro cell model for cytochrome P450 induction.

Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, Yergey JA, Nicoll-Griffith DA. Silva JM, et al. Among authors: yergey ja. Drug Metab Dispos. 1998 May;26(5):490-6. Drug Metab Dispos. 1998. PMID: 9571231

8

Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor.

Nicoll-Griffith DA, Falgueyret JP, Silva JM, Morin PE, Trimble L, Chan CC, Clas S, Leger S, Wang Z, Yergey JA, Riendeau D. Nicoll-Griffith DA, et al. Among authors: yergey ja. Drug Metab Dispos. 1999 Mar;27(3):403-9. Drug Metab Dispos. 1999. PMID: 10064573

9

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.

Nicoll-Griffith DA, Silva JM, Chauret N, Day S, Leblanc Y, Roy P, Yergey JA, Dixit R, Patrick D. Nicoll-Griffith DA, et al. Among authors: yergey ja. Drug Metab Dispos. 2001 Feb;29(2):159-65. Drug Metab Dispos. 2001. PMID: 11159806

10

Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.

Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ. Li C, et al. Among authors: yergey ja. Drug Metab Dispos. 2001 Mar;29(3):232-41. Drug Metab Dispos. 2001. PMID: 11181489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters